Zacks Rating on AbbVie (ABBV)

AbbVie (ABBV) : 6 brokerage houses believe that AbbVie (ABBV) is a Strong Buy at current levels. 6 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on AbbVie (ABBV). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 13 Wall Street Analysts endorse the stock as a Buy with a rating of 2.23.

AbbVie (ABBV) stock is expected to deviate a maximum of $11.15 from the average target price of $71.75 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $90 and the most muted being $47.


AbbVie Inc. has dropped 0.85% in the last five trading days, however, the shares have posted positive gains of 2.88% in the last 4 weeks. AbbVie Inc. is up 9.97% in the last 3-month period. Year-to-Date the stock performance stands at 14.96%. AbbVie (NYSE:ABBV): On Tuesdays trading session , Opening price of the stock was $67.26 with an intraday high of $67.49. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $65.99. However, the stock managed to close at $66.17, a loss of 1.25% for the day. On the previous day, the stock had closed at $67.01. The total traded volume of the day was 10,227,754 shares.

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.